These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 9272331)

  • 1. Epidemiological determinants of pertussis.
    Miller E; Gay NJ
    Dev Biol Stand; 1997; 89():15-23. PubMed ID: 9272331
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Investigating the pertussis resurgence in England and Wales, and options for future control.
    Choi YH; Campbell H; Amirthalingam G; van Hoek AJ; Miller E
    BMC Med; 2016 Sep; 14(1):121. PubMed ID: 27580649
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The epidemiology of pertussis in England and Wales.
    Miller E; Vurdien JE; White JM
    Commun Dis Rep CDR Rev; 1992 Dec; 2(13):R152-4. PubMed ID: 1285134
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Waning vaccine immunity in teenagers primed with whole cell and acellular pertussis vaccine: recent epidemiology.
    Sheridan SL; Frith K; Snelling TL; Grimwood K; McIntyre PB; Lambert SB
    Expert Rev Vaccines; 2014 Sep; 13(9):1081-106. PubMed ID: 25093268
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Live pertussis vaccines: will they protect against carriage and spread of pertussis?
    Locht C
    Clin Microbiol Infect; 2016 Dec; 22 Suppl 5():S96-S102. PubMed ID: 28341014
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Whooping cough, twenty years from acellular vaccines introduction.
    Greco D; Esposito S; Tozzi A; Pandolfi E; Icardi G; Giammanco A
    Ann Ig; 2015; 27(2):415-31. PubMed ID: 26051141
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of immunisation on pertussis transmission in England and Wales.
    Rohani P; Earn DJ; Grenfell BT
    Lancet; 2000 Jan; 355(9200):285-6. PubMed ID: 10675078
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Control of pertussis in the world.
    Galazka A
    World Health Stat Q; 1992; 45(2-3):238-47. PubMed ID: 1462658
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The cost of epidemiological transition: a study of a decrease in pertussis vaccination coverage.
    Girard DZ
    Health Policy; 2005 Nov; 74(3):287-303. PubMed ID: 15951048
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A modelling analysis of pertussis transmission and vaccination in Rio de Janeiro, Brazil.
    Luz PM; Codeço CT; Werneck GL; Struchiner CJ
    Epidemiol Infect; 2006 Aug; 134(4):850-62. PubMed ID: 16316489
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of an accelerated immunisation schedule on pertussis in England and Wales.
    White JM; Fairley CK; Owen D; Matthews RC; Miller E
    Commun Dis Rep CDR Rev; 1996 May; 6(6):R86-91. PubMed ID: 8664929
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Can vaccine legacy explain the British pertussis resurgence?
    Riolo MA; King AA; Rohani P
    Vaccine; 2013 Dec; 31(49):5903-8. PubMed ID: 24139837
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adolescent and adult pertussis: disease burden and prevention.
    Edwards K; Freeman DM
    Curr Opin Pediatr; 2006 Feb; 18(1):77-80. PubMed ID: 16470167
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Modelling the effect of changes in vaccine effectiveness and transmission contact rates on pertussis epidemiology.
    Pesco P; Bergero P; Fabricius G; Hozbor D
    Epidemics; 2014 Jun; 7():13-21. PubMed ID: 24928665
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pertussis: increasing disease as a consequence of reducing transmission.
    Aguas R; Gonçalves G; Gomes MG
    Lancet Infect Dis; 2006 Feb; 6(2):112-7. PubMed ID: 16439331
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term follow-up of Swedish children vaccinated with acellular pertussis vaccines at 3, 5, and 12 months of age indicates the need for a booster dose at 5 to 7 years of age.
    Gustafsson L; Hessel L; Storsaeter J; Olin P
    Pediatrics; 2006 Sep; 118(3):978-84. PubMed ID: 16950988
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectiveness of maternal pertussis vaccination in England: an observational study.
    Amirthalingam G; Andrews N; Campbell H; Ribeiro S; Kara E; Donegan K; Fry NK; Miller E; Ramsay M
    Lancet; 2014 Oct; 384(9953):1521-8. PubMed ID: 25037990
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rationale for pertussis booster vaccination throughout life in Europe.
    Zepp F; Heininger U; Mertsola J; Bernatowska E; Guiso N; Roord J; Tozzi AE; Van Damme P
    Lancet Infect Dis; 2011 Jul; 11(7):557-70. PubMed ID: 21600850
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Acellular pertussis vaccine (Pa)].
    Magdzik W
    Przegl Epidemiol; 1995; 49(3):325-9. PubMed ID: 7491431
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Improved pertussis vaccines based on adjuvants that induce cell-mediated immunity.
    Allen AC; Mills KH
    Expert Rev Vaccines; 2014 Oct; 13(10):1253-64. PubMed ID: 25017925
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.